Professor Klaus Strein has been nominated as a member of NovImmune’s Board of Directors.

Professor Strein has had an impressive pharma industry career, which began when he joined Boehringer Mannheim (BM) as Head of Cardiovascular Pharmacology in 1979.

He was promoted to Head of Pharma at BM in 1997 and then Head of Pharma Research when the company was taken over by Roche.

Since then, Prof Strein has worked as Global Head of Pharma Research and is currently in charge of all Pharma Research and Early Development (pRED) activities in connection with the generation, optimisation, early technical development and formulation of small molecules, therapeutic proteins, RNA therapeutics and therapeutic stem cells.

He commented that “it is a great opportunity to become part of an already well established biotech like NovImmune where technologies and products will potentially deliver superior treatment modalities to ill-served patient populations”.

Jack Barbut, NovImmune CEO, added: “I am very pleased that NovImmune was able to attract such a high   caliber personality from the pharma world. The nomination of Prof Strein as new Board member will strengthen and widen the expertise of the current team, and will be an important asset for supporting and implementing NovImmune’s corporate development.”